US Patent Issued to MEDIMMUNE on Aug. 25 for "Molecules with altered neonate Fc receptor binding having enhanced therapeutic and diagnostic properties" (Maryland Inventors)

ALEXANDRIA, Va., Aug. 25 -- United States Patent no. 12,715,933, issued on Aug. 25, was assigned to MEDIMMUNE LLC.

"Molecules with altered neonate Fc receptor binding having enhanced therapeutic and diagnostic properties" was invented by Ping Tsui (Gaithersburg, Md.), Martin Borrok (Gaithersburg, Md.), William Dall'acqua (Gaithersburg, Md.), Yanli Wu (Gaithersburg, Md.) and Nurten Beyaz-Kavuncu (Gaithersburg, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc regio...